Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Pharma CEO Paul Hudson Discusses Leadership And Launches

Executive Summary

Hudson has gained his footing running Novartis' pharma business. Now, he's preparing to launch seven new drugs by 2020 while growing Cosentyx, Entresto and other in-line products.

You may also be interested in...



Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay

Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.

Novartis Finds All-Important Head Of Oncology Business At Pfizer

Novartis has tempted Liz Barrett away from Pfizer to become CEO of Novartis Oncology, but the appointment of a new global drug development head at the Swiss multinational has yet to be announced.

Schultz Swings The Cleaver At Teva, Cutting 25% Of The Workforce

Troubled Teva has been preparing employees for layoffs, but the final plan will reshape the generic drug giant entirely with 14,000 jobs being cut in a scramble to stabilize the company. Every business area and geography will be affected.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100220

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel